IDEAYA Biosciences, Inc. (IDYA) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-17
Business type: Asset play
How it makes money
It receives cash from pharmaceutical partners through upfront payments and milestones.
The company generates cash by licensing its drug candidates to larger pharmaceutical companies. This provides upfront payments and future royalties.
Payments are triggered when clinical milestones are achieved or through royalties on sales made by partners in certain territories.
What protects it: the moat
It relies on its ability to target specific genetic drivers of cancer.
Management claims the company's advantage is its ability to use biomarkers—biological indicators of disease—to create tailored therapies for specific mutations.
What growth costs
It must fund expensive clinical trials and build a sales organization.
The company spends heavily on research and development. It also needs to invest in its commercial infrastructure to prepare for future drug sales.
What could damage it
Poor trial results for darovasertib would prevent receiving milestone payments from partners.
The company's ability to earn money is tied to the success of its clinical programs. If the data for its most advanced drug fails to meet expectations, partners will not pay the scheduled milestones.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.